BR112014013495A8 - anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 - Google Patents
anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3Info
- Publication number
- BR112014013495A8 BR112014013495A8 BR112014013495A BR112014013495A BR112014013495A8 BR 112014013495 A8 BR112014013495 A8 BR 112014013495A8 BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A8 BR112014013495 A8 BR 112014013495A8
- Authority
- BR
- Brazil
- Prior art keywords
- her3
- antibodies
- domain
- ligand
- fragments
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 8
- 239000012634 fragment Substances 0.000 abstract 6
- 230000001419 dependent effect Effects 0.000 abstract 4
- 230000019491 signal transduction Effects 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566912P | 2011-12-05 | 2011-12-05 | |
| PCT/IB2012/056956 WO2013084151A2 (en) | 2011-12-05 | 2012-12-04 | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014013495A8 true BR112014013495A8 (pt) | 2017-06-13 |
| BR112014013495A2 BR112014013495A2 (pt) | 2017-06-13 |
Family
ID=47561692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014013495A BR112014013495A2 (pt) | 2011-12-05 | 2012-12-04 | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 |
Country Status (16)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2941030A1 (en) | 2014-02-28 | 2015-09-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| ES2833599T3 (es) * | 2014-02-28 | 2021-06-15 | Merus Nv | Anticuerpo que se une a ERBB-2 y ERBB-3 |
| WO2016011167A1 (en) | 2014-07-16 | 2016-01-21 | Dana-Farber Cancer Institute, Inc., Et Al | Her3 inhibition in low-grade serous ovarian cancers |
| CN104530237B (zh) * | 2014-12-31 | 2017-09-05 | 百泰生物药业有限公司 | 抗Her1的治疗性抗体 |
| NZ742290A (en) | 2015-10-23 | 2019-11-29 | Merus Nv | Binding molecules that inhibit cancer growth |
| JP6729926B2 (ja) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法 |
| ES3037145T3 (en) * | 2016-09-15 | 2025-09-29 | Univ Stuttgart | Antigen binding protein against her3 |
| KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
| CA3063849A1 (en) | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| MA49846B1 (fr) | 2017-08-09 | 2025-05-30 | Merus N.V. | Anticorps liant egfr et cmet |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| AU2010242914B2 (en) * | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| CN105999263B (zh) * | 2009-11-13 | 2021-06-29 | 第一三共欧洲有限公司 | 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法 |
| RU2568051C2 (ru) * | 2010-04-09 | 2015-11-10 | Авео Фармасьютикалз, Инк. | АНТИТЕЛА К ErbB3 |
| TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| DK2707391T3 (en) * | 2011-05-13 | 2018-02-05 | Gamamabs Pharma | ANTIBODIES AGAINST HER3 |
| WO2013016714A1 (en) * | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies | Sur-binding proteins against erbb3 |
-
2012
- 2012-12-04 CA CA2857939A patent/CA2857939A1/en not_active Abandoned
- 2012-12-04 BR BR112014013495A patent/BR112014013495A2/pt not_active Application Discontinuation
- 2012-12-04 MX MX2014006731A patent/MX2014006731A/es unknown
- 2012-12-04 EA EA201491120A patent/EA201491120A1/ru unknown
- 2012-12-04 TW TW101145508A patent/TW201331225A/zh unknown
- 2012-12-04 UY UY0001034488A patent/UY34488A/es not_active Application Discontinuation
- 2012-12-04 IN IN4374CHN2014 patent/IN2014CN04374A/en unknown
- 2012-12-04 WO PCT/IB2012/056956 patent/WO2013084151A2/en active Application Filing
- 2012-12-04 KR KR1020147018336A patent/KR20140099315A/ko not_active Withdrawn
- 2012-12-04 JP JP2014545420A patent/JP2015500830A/ja active Pending
- 2012-12-04 AU AU2012349739A patent/AU2012349739A1/en not_active Abandoned
- 2012-12-04 EP EP12816130.4A patent/EP2788381A2/en not_active Withdrawn
- 2012-12-04 CN CN201280068966.8A patent/CN104093742A/zh active Pending
- 2012-12-04 SG SG11201402784WA patent/SG11201402784WA/en unknown
- 2012-12-05 AR ARP120104559A patent/AR089085A1/es unknown
-
2014
- 2014-06-02 IL IL232950A patent/IL232950A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR089085A1 (es) | 2014-07-30 |
| EA201491120A1 (ru) | 2015-07-30 |
| KR20140099315A (ko) | 2014-08-11 |
| IL232950A0 (en) | 2014-07-31 |
| TW201331225A (zh) | 2013-08-01 |
| BR112014013495A2 (pt) | 2017-06-13 |
| SG11201402784WA (en) | 2014-06-27 |
| WO2013084151A2 (en) | 2013-06-13 |
| UY34488A (es) | 2013-07-31 |
| EP2788381A2 (en) | 2014-10-15 |
| JP2015500830A (ja) | 2015-01-08 |
| AU2012349739A1 (en) | 2014-06-26 |
| CA2857939A1 (en) | 2013-06-13 |
| IN2014CN04374A (enrdf_load_html_response) | 2015-09-04 |
| CN104093742A (zh) | 2014-10-08 |
| MX2014006731A (es) | 2015-06-04 |
| WO2013084151A3 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014013495A2 (pt) | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3 | |
| BR112014013568A8 (pt) | anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3 | |
| CL2012003093A1 (es) | Anticuerpo aislado multivalente que tiene al menos dos dominios de union a receptores para dos diferentes sitios de union de un receptor diana lrp6 que inhiben una via canonica de transduccion de señal wnt; anticuerpo aislado biparatopico que une lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; metodo de obtencion de dicho anticuerpo; y su uso para tratar cancer. | |
| CY1120181T1 (el) | Αντι-cd40 αντισωματα | |
| HRP20090213A2 (hr) | Postupak i međuprodukti u pripravi inhibitora integraze | |
| JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
| GEP201706605B (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| BR112014006390A2 (pt) | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano | |
| AU2018256540A1 (en) | Novel asphalt binder additive compositions and methods of use | |
| WO2008121615A3 (en) | Antibody formulation | |
| BR112014011594A2 (pt) | anticorpos anti-il-36r | |
| WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
| BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
| MY159679A (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| BR112014011351A2 (pt) | inibidores de acc e usos dos mesmos | |
| MX374826B (es) | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. | |
| NZ604510A (en) | Dilutable biocidal compositions and methods of use | |
| UA114712C2 (uk) | Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування | |
| PL2013236T3 (pl) | Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK | |
| AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
| WO2010007376A3 (en) | Compositions monovalent for cd28 binding and methods of use | |
| BR112013031943A2 (pt) | "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos". | |
| BR112012016309A2 (pt) | "porção, composição farmacêutica, uso de uma quantidade eficaz da porção, método para identificar uma porção que se liga a um domínio semelhante a ig de um receptor do fator de crescimento endotelial vascular (receptor de vegf), e, anticorpo isolado ou uma porção de ligação de antígeno deste". | |
| MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
| WO2010042636A3 (en) | Telomerase inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |